Salbutamol wzf 4 mg (DrugBank: Salbutamol)
14 diseasesID | Disease name (Link within this page) | Number of trials |
---|---|---|
3 | Spinal muscular atrophy | 0 |
11 | Myasthenia | 1 |
12 | Congenital myasthenic syndrome | 0 |
13 | Multiple sclerosis/Neuromyelitis optica | 0 |
49 | Systemic lupus erythematosus | 0 |
85 | Idiopathic interstitial pneumonia | 0 |
86 | Pulmonary arterial hypertension | 0 |
89 | Lymphangioleiomyomatosis | 0 |
111 | Congenital myopathy | 0 |
113 | Muscular dystrophy | 0 |
228 | Bronchiolitis obliterans | 0 |
231 | Alpha-1-antitrypsin deficiency | 0 |
256 | Muscle glycogenosis | 0 |
299 | Cystic fibrosis | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2019-000895-40-DK (EUCTR) | 28/03/2019 | 26/02/2019 | Beta-agonist Efficacy and Tolerability as Adjuvant therapy in Myasthenia Gravis | Beta-agonist Efficacy and Tolerability as Adjuvant therapy in Myasthenia Gravis - BETA-MG | Myasthenia Gravis MedDRA version: 21.1;Level: PT;Classification code 10028417;Term: Myasthenia gravis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] | Trade Name: Salbutamol WZF 4 mg INN or Proposed INN: Salbutamol Other descriptive name: SALBUTAMOL SULFATE PH. EUR. | Aarhus University Hospital | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 30 | Phase 3 | Denmark |